Humacyte
Business Services · North Carolina, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
2525 E NC Highway 54, Durham, North Caro...Phone Number
(919) 313-9633Website
www.humacyte.comRevenue
<$5 MillionStock Symbol
HUMAIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Humacyte
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Explore more
Humacyte Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Humacyte your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Humacyte has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Humacyte recently announced quarterly report
Funding: Get notified immidiatlly once Humacyte has new funding data
Humacyte, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Humacyte launches new products
Congratulate Masked Content for being promoted to Masked Content at Humacyte
Check out if Humacyte is spiking on competitors!
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Humacyte had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Humacyte
Compare insights from companies similar to Humacyte, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Humacyte is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Humacyte is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Humacyte.
Humacyte financials insights
Gather financial insights about Humacyte, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Series B
$150M
2016
Private Equity
$10M
2017
Unspecified
$14.1M
2018
Other Financing Round
$150M
2020
Debt
$2M
2021
Debt
$50M
2023
Debt
$150M
Humacyte Tech Stack
A closer look at the technologies used by Humacyte
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Open Position
Open Position
Open Position
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Humacyte News & Media
Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA
NEW YORK and NEW ORLEANS, Aug. 21, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF continues its investigation into Humacyte, Inc. (NasdaqGS: HUMA) ("Humacyte" or the...Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results
– Phase 3 results highlight benefits of ATEV for patients at higher risk of fistula failure, including all women and men with obesity and diabetes –Board-Certified Vascular and Endovascular Surgeon Performs First Commercial Symvess® Implantation; Cites Bioengineered Blood Vessel as “Revolutionary Advancement”
– Jeromy Brink, MD, Mayo Clinic–trained vascular surgeon in Phoenix, is the first surgeon in Arizona to implant Symvess, the first and only FDA-approved bioengineered human blood vessel –Humacyte Announces Second Quarter 2026 Financial Results and Provides Business Update
– Breakthrough results from V012 dialysis access Phase 3 study, where ATEV was observed to outperform AV fistula; supplemental Biologic License Application (sBLA) for dialysis access to be filed with the Food and Drug Administration (FDA) during the second half of 2026 –
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Humacyte
Sign Up For FreeTo access detailed company insights
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ves... Read More
